ArticleFrontiers in surgery2026
Case report and literature review: the effect of surgical management in intrathoracic pseudomyxoma peritonei.
Article in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intrathoracic metastasis in patients with pseudomyxoma peritonei is extremely rare and carries a poor prognosis. No standard treatment recommendations have been established, and it remains unclear whether surgical treatment can improve the long-term prognostic outcomes. Cases description: A retrospective analysis of the clinical findings of six intrathoracic pseudomyxoma peritonei patients that underwent surgical treatment at the Aerospace Center Hospital between March 2013 and June 2022 was conducted. Five patients exhibited evidence of direct extension into the pleural cavity, and four underwent parietal/visceral pleurectomy to remove as much of the mucinous tissue from the thoracic cavity as possible. One patient underwent the resection of disseminated pleural and lung lesions followed by hyperthermic intrathoracic chemotherapy (HITHOC). One patient exhibited pulmonary metastases and underwent lobectomy. Macroscopic tumor resection was performed in all patients. Patients were monitored for a mean follow-up time of 24 months, and exhibited 1- and 3-year survival rates of 100% (6/6) and 33.3% (2/6), respectively. Conclusion: Intrathoracic pseudomyxoma peritonei is a rare clinical disease associated with a poor prognosis that primarily results following injury to the diaphragm during the surgical treatment of pseudomyxoma peritonei. Cytoreductive surgery to treat thoracic tumors in combination with HITHOC can alleviate the symptoms of this condition and can contribute to better prognostic outcomes. However, it is important to remain attentive to the potential for perioperative complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.